The Use of Commercially Available Alpha-Amylase Compounds to Inhibit and Remove Staphylococcus aureus Biofilms

Bradford Craigen, Aliza Dashiff, Daniel E Kadouri*
Department of Oral Biology, University of Medicine and Dentistry of New Jersey, Newark, NJ, 07101, USA

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 2481
Abstract HTML Views: 2135
PDF Downloads: 441
Total Views/Downloads: 5057
Unique Statistics:

Full-Text HTML Views: 1230
Abstract HTML Views: 1166
PDF Downloads: 318
Total Views/Downloads: 2714

Creative Commons License
© Craigen et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Department of Oral Biology, University of Medicine and Dentistry of New Jersey, Newark, NJ, 07101. Tel: 973-972-7401; Fax: 973-972-0045; E-mail:


Staphylococcus aureus, a versatile human pathogen, is commonly associated with medical device infections. Its capacity to establish and maintain these infections is thought to be related to its ability to form adherent biofilms. In this study, commercially available α-amylase compounds from various biological sources were evaluated for their ability to reduce and prevent biofilm formation of several S. aureus isolates. Our data demonstrates that α-amylase compounds can rapidly detach biofilms of S. aureus, as well as inhibit biofilm formation. Our data also demonstrates that α-amylase compounds have an ability to reduce and disassociate S. aureus cell-aggregates grown in liquid suspension. These findings suggest that commercially available α-amylase compounds could be used in the future to control S. aureus biofilm-related infections.

Keywords: Staphylococcus aureus, α-amylases, Biofilm control, Biofilm-dispersing enzymes.